Discontinued — last reported Q3 '21
Cumulative Gross Unrealized Gains
EquityEli Lilly Cumulative Gross Unrealized Gains decreased by 13.2% to $3.30M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 54.2%, from $7.20M to $3.30M. Over 4 years (FY 2020 to FY 2024), Cumulative Gross Unrealized Gains shows a downward trend with a -47.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ4 2020
Last reportedQ3 2021
Metric ID:
cumulative_gross_unrealized_gainsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.50M | $12.50M | $9.70M | $1.30M | $200.00K | $100.00K | $600.00K | $1.80M | $600.00K | $100.00K | $3.40M | $1.90M | $1.40M | $7.20M | $1.60M | $3.00M | $3.80M | $3.30M |
| QoQ Change | — | -13.8% | -22.4% | -86.6% | -84.6% | -50.0% | +500.0% | +200.0% | -66.7% | -83.3% | >999% | -44.1% | -26.3% | +414.3% | -77.8% | +87.5% | +26.7% | -13.2% |
| YoY Change | — | — | — | — | -98.6% | -99.2% | -93.8% | +38.5% | +200.0% | +0.0% | +466.7% | +5.6% | +133.3% | >999% | -52.9% | +57.9% | +171.4% | -54.2% |
Range$100.00K – $14.50M
CAGR-29.4%
Avg YoY Growth+555.3%
Median YoY Growth+22.0%
Cumulative Gross Unrealized Gains at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cumulative gross unrealized gains?
- Eli Lilly (LLY) reported cumulative gross unrealized gains of $3.30M in Q3 2025.
- How has Eli Lilly's cumulative gross unrealized gains changed year-over-year?
- Eli Lilly's cumulative gross unrealized gains decreased by 54.2% year-over-year, from $7.20M to $3.30M.
- What is the long-term trend for Eli Lilly's cumulative gross unrealized gains?
- Over 4 years (2020 to 2024), Eli Lilly's cumulative gross unrealized gains has grown at a -47.4% compound annual growth rate (CAGR), from $20.90M to $1.60M.